Monday , July 23 2018
Home / KEEP BUT DO NOT DISPLAY / Alerts / Lixisenatide (Lyxumia) has been accepted for review by the FDA.

Lixisenatide (Lyxumia) has been accepted for review by the FDA.

Feb 22, 2013
 

Lixisenatide (Lyxumia) has been accepted for review by the FDA.

French drugmaker Sanofi said on Tuesday that its experimental GLP-1 once-daily diabetes drug lixisenatide (Lyxumia) has been accepted for review by the FDA. Sanofi is set to launch the drug in Europe shortly.